Clinical Trial

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.
Protocol Amendment History 2 changes
critical Trial completed 2026-08-14
notable Enrollment reduced: 68 -> 51 participants 2026-08-14
Trial Details
NCT Number NCT05064319
Lead Sponsor Medical University of South Carolina
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Bipolar Disorder, Cannabis Use, Schizoaffective Disorder, Bipolar Type, Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Enrollment 51 participants
Start Date 2022-02-24
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-13